期刊
JOURNAL OF INFECTIOUS DISEASES
卷 214, 期 -, 页码 S497-S499出版社
OXFORD UNIV PRESS INC
DOI: 10.1093/infdis/jiw352
关键词
chikungunya virus; vaccine; whole-inactivated vaccine; virus-like particle vaccine; alphavirus
资金
- Vaccine Research Center, National Institute of Allergy and Infectious Diseases, National Institutes of Health
Chikungunya virus (CHIKV) is a global public health threat, having been identified in >60 countries in Asia, Africa, Europe, and the Americas. There is no cure for or licensed vaccine against CHIKV infection. Initial attempts at CHIKV vaccine development began in the early 1960s. Whole-inactivated and virus-like particle (VLP) vaccines are 2 of the current approaches being evaluated. Success of these approaches is dependent on a safe, well-tolerated vaccine that is immunogenic and deployable in regard to manufacturing, stability, and delivery characteristics.
作者
我是这篇论文的作者
点击您的名字以认领此论文并将其添加到您的个人资料中。
推荐
暂无数据